

BSW Formulary Update – Following APC Dec 2020 meeting

New additions to the BSWformulary

- [ORAL Semaglutide 3mg, 7mg, 14mg tablets \(Rybelsus®\)](#) added for the treatment of adults with insufficiently controlled T2DM. Amber TLS. Rybelsus® is unique in that it is the **first oral GLP1 receptor agonist**. It has very specific administration requirements and should be taken on an empty stomach, swallowed whole with ≤120ml of water (preferably a sip), and no food, drink or other oral medicines should be taken for up to 30 mins. AMBER TLS. **Prescribe in line with [BSW Rybelsus prescribing guidance](#)**

Changes in Traffic Light Status (TLS)

- [Injectable GLP1s](#) have been assigned a GREEN TLS for BaNES/Wilts and can be initiated in primary care *where a practice/HCP feels they have sufficient knowledge to initiate without specialist support*. Injectable GLP1s retain an AMBER TLS in Swindon. Further training and education for primary care is required and will be addressed as part of the BSW diabetes transformation workstream.
- [Sildenafil for Digital Ulceration and Severe Raynaud's](#) (unlicensed indication) moved from RED TLS to Amber w SCA

TLS Aligned for BSW

- **DMARD monitoring** - DMARDs used for Rheumatology and Dermatology indications at GWH have been brought into an established RUH/SFT Shared Care Agreement. [BSW Summary of Shared Care Guidelines and Monitoring of Disease Modifying Drugs \(DMARDs\) in Adults: Rheumatology, Dermatology & Gastroenterology](#)

New and Updated Prescribing Guidelines

- **Updated** - [BSW guidance on B12 supplements during COVID pandemic](#) (includes newly licensed 1mg cyanocobalamin oral tablets (Orobalin))
- **New** - [BSW Investigation, treatment and review of Vitamin B12 \(cobalamin\) deficiency](#) (adapted for BSW from a historic BCAP document and includes information on appropriate deprescribing)
- **Updated** - BSW Management of Infections in Primary Care, [Full Guideline](#); [Quick Ref Guide adults](#); [Quick Ref Guide children](#) (incorporates human and animal bite guidance exactly as per NICE NG184)

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net

What the BSW CCG formulary team are currently working on

- Producing a policy/pathway and prescribing criteria for use of melatonin
- Updating the Vitamin D guidance
- Updating the constipation guidance
- Working on the Paediatric formulary chapter
- Updating the pain management documents
- Reviewing formulary position of Cox-2 inhibitors
- Position statements on various devices
- Working with AWP on an oral antipsychotic SCA